ARIEL4: A study of rucaparib versus chemotherapy in BRCA-positive ovarian, fallopian tube or primary peritoneal cancer
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Women may be able to participate if they have:
- relapsed, high-grade ovarian, fallopian tube or primary peritoneal cancer
- had two previous chemotherapy regimens
- a BRCA1 or BRCA2 mutation
- no prior treatment with PARP inhibitors or single-agent paclitaxel
- not required treatment with chemotherapy in the past six months.
This is not an exhaustive list. Women interested in participating in a clinical trial should speak to their own doctor about what other criteria might apply.
About the trial
The aim of the trial is to fully understand the benefits of a PARP inhibitor versus standard chemotherapy for BRCA-positive women who have had two previous treatments.
Drugs involved in this trial:
- rucaparib, a PARP inhibitor
- paclitaxel, a standard chemotherapy drug
- carboplatin or cisplatin, standard chemotherapy drugs.
Women in this trial will be randomised (placed into a treatment group by a computer) into one of three treatment types:
- rucaparib – oral tablets to be taken twice a day in a 28-day cycle.
- single-agent paclitaxel – intravenously for women who are platinum-resistant or partially sensitive.
- single-agent platinum or two chemotherapy drugs – to be given at the doctor's discretion.
If a woman's cancer progresses on the trial and she is receiving one of the chemotherapy drugs there is the option for her to move over onto the rucarparib treatment arm.